RenovoRx, Inc.
RNXT· Nasdaq
Released Nov 13, 2024, after the close
10-Q filed Nov 13, 2024, 44 days after period end · 0001493152-24-045137
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Net Income | -$2.47M | -$1.42M | -$2.14M | -$1.51M |
| EPS Diluted | -$0.10 | -$0.13 | -$0.24 | -$0.27 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
RenovoRx, Inc. · CIK 1574094 · Engraved from SEC EDGAR